Development
ImmunoPrecise Antibodies Ltd.
IPA
$0.6724
-$0.0296-4.22%
NASDAQ
| 10/31/2023 | 07/31/2023 | 04/30/2023 | 01/31/2023 | 10/31/2022 | |
|---|---|---|---|---|---|
| Revenue | 16.78M | 16.15M | 15.53M | 15.51M | 15.48M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 16.78M | 16.15M | 15.53M | 15.51M | 15.48M |
| Cost of Revenue | 7.84M | 7.30M | 6.85M | 6.68M | 6.80M |
| Gross Profit | 8.94M | 8.85M | 8.68M | 8.83M | 8.67M |
| SG&A Expenses | 15.23M | 15.60M | 15.43M | 15.44M | 14.79M |
| Depreciation & Amortization | 2.90M | 3.09M | 3.32M | 2.74M | 2.37M |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 28.20M | 31.22M | 35.30M | 35.24M | 35.20M |
| Operating Income | -11.42M | -15.08M | -19.77M | -19.73M | -19.73M |
| Income Before Tax | -12.54M | -16.25M | -20.99M | -20.08M | -19.53M |
| Income Tax Expenses | -661.90K | -780.20K | -897.00K | -113.60K | -26.60K |
| Earnings from Continuing Operations | -11.88 | -15.47 | -20.09 | -19.97 | -19.50 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -11.88M | -15.47M | -20.09M | -19.97M | -19.50M |
| EBIT | -11.42M | -15.08M | -19.77M | -19.73M | -19.73M |
| EBITDA | -8.84M | -11.79M | -16.29M | -16.67M | -16.25M |
| EPS Basic | -0.47 | -0.62 | -0.81 | -0.83 | -0.85 |
| Normalized Basic EPS | -0.26 | -0.36 | -0.48 | -0.50 | -0.51 |
| EPS Diluted | -0.47 | -0.62 | -0.81 | -0.83 | -0.85 |
| Normalized Diluted EPS | -0.26 | -0.36 | -0.48 | -0.50 | -0.51 |
| Average Basic Shares Outstanding | 100.08M | 99.90M | 99.59M | 95.31M | 89.80M |
| Average Diluted Shares Outstanding | 100.08M | 99.90M | 99.59M | 95.31M | 89.80M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |